
Suzanne Kamel-Reid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4495561/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>BCR–ABL1</i> transcript doubling time as a predictor for treatmentâ€free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. British Journal of Haematology, 2022, 196, 136-145.	2.5	4
2	Optimal duration of imatinib treatment/deep molecular response for treatmentâ€free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. British Journal of Haematology, 2021, 193, 779-791.	2.5	10
3	The value of defining molecular resistance in patients with progressive EGFR and ALK-driven lung cancer in a public system Journal of Clinical Oncology, 2021, 39, 3126-3126.	1.6	0
4	The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches. Gynecologic Oncology, 2021, 162, 97-106.	1.4	3
5	The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia. Leukemia Research, 2020, 88, 106285.	0.8	Ο
6	HPV-independent Vulvar Squamous Cell Carcinoma is Associated With Significantly Worse Prognosis Compared With HPV-associated Tumors. International Journal of Gynecological Pathology, 2020, 39, 391-399.	1.4	41
7	Assessing the Diagnostic Yield of Targeted Next-Generation Sequencing for Melanoma and Gastrointestinal Tumors. Journal of Molecular Diagnostics, 2020, 22, 467-475.	2.8	5
8	A 4-gene signature from histologically normal surgical margins predicts local recurrence in patients with oral carcinoma: clinical validation. Scientific Reports, 2020, 10, 1713.	3.3	15
9	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical Cancer Research, 2020, 26, 2477-2486.	7.0	16
10	Latency and interval therapy affect the evolution in metastatic colorectal cancer. Scientific Reports, 2020, 10, 581.	3.3	6
11	Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia. Haematologica, 2020, 106, 56-63.	3.5	23
12	Performance Comparison of Different Analytic Methods in Proficiency Testing for Mutations in the BRAF, EGFR, and KRAS Genes: A Study of the College of American Pathologists Molecular Oncology Committee. Archives of Pathology and Laboratory Medicine, 2019, 143, 1203-1211.	2.5	12
13	Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 84-91.	0.8	36
14	Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, e338-e345.	2.6	14
15	Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels. Journal of Molecular Diagnostics, 2019, 21, 261-273.	2.8	36
16	Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. Journal of Pathology: Clinical Research, 2019, 5, 115-129.	3.0	96
17	Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing–Based Oncology Assays. Archives of Pathology and Laboratory Medicine, 2019, 143, 463-471.	2.5	32
18	Non-small cell lung cancer (NSCLC) next generation sequencing (NGS) using the Oncomine Comprehensive Assay (OCA) v3: Integrating expanded genomic sequencing into the Canadian publicly funded health care model Journal of Clinical Oncology, 2019, 37, 2620-2620.	1.6	9

#	Article	IF	CITATIONS
19	AML refractory to primary induction with Ida-FLAG has a poor clinical outcome. Leukemia Research, 2018, 68, 22-28.	0.8	7
20	Translation of Knowledge to Practice—Improving Awareness in NSCLC Molecular Testing. Journal of Thoracic Oncology, 2018, 13, 1004-1011.	1.1	8
21	Improving validation methods for molecular diagnostics: application of Bland-Altman, Deming and simple linear regression analyses in assay comparison and evaluation for next-generation sequencing. Journal of Clinical Pathology, 2018, 71, 117-124.	2.0	7
22	T cell clonality assessment: past, present and future. Journal of Clinical Pathology, 2018, 71, 195-200.	2.0	52
23	Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience. Clinical Colorectal Cancer, 2018, 17, 73-79.	2.3	17
24	Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. International Journal of Cancer, 2018, 142, 57-65.	5.1	23
25	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 168, 159-168.	2.5	27
26	Comparison of Laboratory-Developed Tests and FDA-Approved Assays for <i>BRAF, EGFR,</i> and <i>KRAS</i> Testing. JAMA Oncology, 2018, 4, 838.	7.1	30
27	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma. JAMA Oncology, 2018, 4, e173776.	7.1	116
28	Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies. JCO Precision Oncology, 2018, 2, 1-20.	3.0	0
29	Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms. Blood, 2018, 132, 2201-2205.	1.4	4
30	The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. Blood Advances, 2018, 2, 2658-2671.	5.2	47
31	The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. Lung Cancer, 2018, 123, 22-29.	2.0	28
32	Clinical Utility of Nextâ€generation Sequencing in the Management of Myeloproliferative Neoplasms: A Singleâ€Center Experience. HemaSphere, 2018, 2, e44.	2.7	19
33	Additional germline findings from a tumor profiling program. BMC Medical Genomics, 2018, 11, 65.	1.5	16
34	Lung cancer in never smokers from the Princess Margaret Cancer Centre. Oncotarget, 2018, 9, 22559-22570.	1.8	20
35	Upfront next generation sequencing in NSCLC: A publicly funded perspective Journal of Clinical Oncology, 2018, 36, 12062-12062.	1.6	2
36	Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nature Communications, 2017, 8, 15086.	12.8	107

#	Article	IF	CITATIONS
37	Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer, 2017, 109, 137-144.	2.0	120
38	Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies. Archives of Pathology and Laboratory Medicine, 2017, 141, 759-775.	2.5	29
39	Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer. Radiotherapy and Oncology, 2017, 123, 195-202.	0.6	43
40	Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels. Journal of Molecular Diagnostics, 2017, 19, 341-365.	2.8	524
41	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology, 2017, 44, 187-197.	2.2	76
42	A Window Into Clinical Next-Generation Sequencing–Based Oncology Testing Practices. Archives of Pathology and Laboratory Medicine, 2017, 141, 1679-1685.	2.5	24
43	Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC). Lung Cancer, 2017, 111, 23-29.	2.0	160
44	Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBFâ€AML) – a single center analysis. Hematological Oncology, 2017, 35, 810-813.	1.7	2
45	Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood Advances, 2017, 1, 1729-1738.	5.2	48
46	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	2.4	58
47	The Use of Targeted Therapies for Precision Medicine in Oncology. Clinical Chemistry, 2016, 62, 1556-1564.	3.2	10
48	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma. Archives of Pathology and Laboratory Medicine, 2016, 140, 355-357.	2.5	9
49	Laboratory Investigation of Myeloproliferative Neoplasms (MPNs). American Journal of Clinical Pathology, 2016, 146, 408-422.	0.7	30
50	Testing <i>ERBB2</i> p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Journal of Physical Education and Sports Management, 2016, 2, a001016.	1.2	5
51	Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics. Journal of Molecular Diagnostics, 2016, 18, 842-850.	2.8	35
52	A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma. Journal of Clinical Pathology, 2016, 69, 607-611.	2.0	15
53	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Medicine, 2016, 8, 109.	8.2	211
54	Extracorporeal photopheresis in solid organ transplant–associated acute graftâ€versusâ€host disease. Transfusion, 2016, 56, 962-969.	1.6	12

#	Article	IF	CITATIONS
55	Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients. British Journal of Cancer, 2016, 114, 616-622.	6.4	17
56	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genetics in Medicine, 2016, 18, 128-136.	2.4	83
57	Prognostic and predictive effects of TP53 mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2016, 34, 11585-11585.	1.6	6
58	Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients Journal of Clinical Oncology, 2016, 34, 1532-1532.	1.6	2
59	Association of <i>isocitrate dehydorgenase-1</i> (<i>IDH-1</i>) mutations with elevated oncometabolite 2-hydroxyglutarate (2HG) in advanced colorectal cancer Journal of Clinical Oncology, 2016, 34, 627-627.	1.6	6
60	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. Oncotarget, 2016, 7, 25632-25639.	1.8	9
61	Molecular profiling of advanced biliary cancer: Lost in translation from bench to bedside Journal of Clinical Oncology, 2016, 34, 283-283.	1.6	2
62	Integration of somatic molecular profiling for rare epithelial gynaecologic cancer patients Journal of Clinical Oncology, 2016, 34, 5509-5509.	1.6	0
63	<i>IDH</i> -1/2mutations and associated oncometabolite 2-hydroxyglutarate (2-HG) in solid tumors Journal of Clinical Oncology, 2016, 34, e23210-e23210.	1.6	0
64	Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome Journal of Clinical Oncology, 2016, 34, 5579-5579.	1.6	0
65	Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2016, 34, e20527-e20527.	1.6	0
66	Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing JAK1/2 Inhibitor Therapy. Blood, 2016, 128, 4263-4263.	1.4	0
67	Malignant Melanoma of Vulva and Vagina. Journal of Lower Genital Tract Disease, 2015, 19, 350-353.	1.9	58
68	Phase II study of PX-866 in recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1270-4.	1.2	77
69	Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease. Annals of Surgical Oncology, 2015, 22, 1950-1958.	1.5	16
70	Mixed fields on RhD typing as an indication of loss of heterozygosity on chromosome 1p in acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 2196-2199.	1.3	1
71	Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2015, 33, 11060-11060.	1.6	2
72	Prognostic effect of single versus multiple somatic mutations in non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2015, 33, 7521-7521.	1.6	3

#	Article	IF	CITATIONS
73	Next-generation sequencing: Profiling gallbladder cancer (GBC) Journal of Clinical Oncology, 2015, 33, 286-286.	1.6	2
74	Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status Journal of Clinical Oncology, 2015, 33, 1532-1532.	1.6	0
75	Personalized treatment outcomes in never smokers with advanced non-small cell lung cancer (NSCLC) in the Princess Margaret Cancer Centre Journal of Clinical Oncology, 2015, 33, e19006-e19006.	1.6	Ο
76	<i>EGFR</i> mutations in NSCLC: Does ethnicity influence outcomes?. Journal of Clinical Oncology, 2015, 33, e17633-e17633.	1.6	0
77	Molecular profiling and targeted therapy in advanced endometrial cancer Journal of Clinical Oncology, 2015, 33, 5589-5589.	1.6	0
78	Knowledge of genetic testing for hereditary kidney cancer in Canada is lacking: The results of the Canadian national hereditary kidney cancer needs assessment survey. Canadian Urological Association Journal, 2014, 8, 832.	0.6	5
79	Personalized Medicine: CCO's Vision, Accomplishments and Future Plans. Healthcare Quarterly, 2014, 17, 41-43.	0.7	1
80	Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response. Leukemia and Lymphoma, 2014, 55, 2398-2401.	1.3	1
81	Genomic testing in cancer: Patient knowledge, attitudes, and expectations. Cancer, 2014, 120, 3066-3073.	4.1	72
82	Imatinib 800Âmg daily induces deeper molecular responses than imatinib 400Âmg daily: results of <scp>SWOG</scp> S0325, an intergroup randomized <scp>PHASE II</scp> trial in newly diagnosed chronic phase chronic myeloid leukaemia. British Journal of Haematology, 2014, 164, 223-232.	2.5	56
83	Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer, 2014, 120, 603-610.	4.1	64
84	Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing. Journal of Thoracic Oncology, 2014, 9, 947-956.	1.1	72
85	Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis?. Human Molecular Genetics, 2014, 23, 2618-2628.	2.9	46
86	A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 87-92.	0.4	21
87	Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecologic Oncology, 2014, 135, 184-189.	1.4	84
88	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Investigational New Drugs, 2014, 32, 1005-1016.	2.6	29
89	<i>BCR/ABL</i> level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. American Journal of Hematology, 2014, 89, 626-632.	4.1	36
90	Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC) Journal of Clinical Oncology, 2014, 32, 5506-5506.	1.6	2

#	Article	IF	CITATIONS
91	A targeted intervention to improve awareness to molecular testing in NSCLC Journal of Clinical Oncology, 2014, 32, 6547-6547.	1.6	1
92	Lung cancer in never-smokers from the Princess Margaret Cancer Centre Journal of Clinical Oncology, 2014, 32, 8099-8099.	1.6	1
93	Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Centre experience Journal of Clinical Oncology, 2014, 32, 459-459.	1.6	1
94	Molecular profiling of patients (pts) with advanced colorectal cancer (CRC): Princess Margaret Cancer Center experience Journal of Clinical Oncology, 2014, 32, 3572-3572.	1.6	0
95	Biomarker testing and time-to-treatment decision in patients with advanced non-small cell lung cancer Journal of Clinical Oncology, 2014, 32, 6595-6595.	1.6	0
96	Retrospective Analysis of Allogeneic Transplant Outcomes in Chronic Myeloid Leukemia Patients with Tyrosine Kinase Inhibitors Failure. Blood, 2014, 124, 4554-4554.	1.4	0
97	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 1182-1191.	2.6	50
98	BCR-ABL1transcript at 3Âmonths predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. British Journal of Haematology, 2013, 160, 630-639.	2.5	26
99	MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma. Journal of Clinical Oncology, 2013, 31, 2903-2911.	1.6	37
100	Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. International Journal of Cancer, 2013, 132, 1547-1555.	5.1	76
101	BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Journal of Molecular Diagnostics, 2013, 15, 565-576.	2.8	32
102	The aryl hydrocarbon receptor nuclear translocator (ARNT) modulates the antioxidant response in AML cells. Leukemia Research, 2013, 37, 1750-1756.	0.8	14
103	CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. Human Pathology, 2013, 44, 2038-2046.	2.0	24
104	Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. Clinical Chemistry, 2013, 59, 938-948.	3.2	46
105	Clinical genomics information management software linking cancer genome sequence and clinical decisions. Genomics, 2013, 102, 140-147.	2.9	14
106	Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype. Human Pathology, 2013, 44, 55-61.	2.0	13
107	Canadian guideline on genetic screening for hereditary renal cell cancers. Canadian Urological Association Journal, 2013, 7, 319.	0.6	30
108	Cytological preparations for molecular pathology. Cancer Cytopathology, 2013, 121, 275-275.	2.4	2

#	Article	IF	CITATIONS
109	A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leukemia and Lymphoma, 2013, 54, 760-766.	1.3	43
110	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS) Journal of Clinical Oncology, 2013, 31, 11002-11002.	1.6	16
111	Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program Journal of Clinical Oncology, 2013, 31, 11016-11016.	1.6	1
112	Phase II study of PX-866 in recurrent glioblastoma Journal of Clinical Oncology, 2013, 31, 2053-2053.	1.6	3
113	Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial Journal of Clinical Oncology, 2013, 31, 6041-6041.	1.6	5
114	Benchmarking population-based EGFR mutation testing in nonsquamous non-small cell lung cancer Journal of Clinical Oncology, 2013, 31, e19032-e19032.	1.6	0
115	A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 255-260.	1.3	45
116	Design and Analytic Validation of BCR-ABL1 Quantitative Reverse Transcription Polymerase Chain Reaction Assay for Monitoring Minimal Residual Disease. Archives of Pathology and Laboratory Medicine, 2012, 136, 33-40.	2.5	24
117	Validation of KRAS Testing for Anti-EGFR Therapeutic Decisions for Patients With Metastatic Colorectal Carcinoma. Archives of Pathology and Laboratory Medicine, 2012, 136, 26-32.	2.5	26
118	Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study. Journal of Clinical Oncology, 2012, 30, 3396-3401.	1.6	99
119	A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood, 2012, 120, 3898-3905.	1.4	154
120	An emerging role for retinoid X receptor α in malignant hematopoiesis. Leukemia Research, 2012, 36, 1075-1081.	0.8	13
121	Equivocal p16 Immunostaining in Squamous Cell Carcinoma of the Head and Neck: Staining Patterns are Suggestive of HPV Status. Head and Neck Pathology, 2012, 6, 422-429.	2.6	44
122	Cancer Genomics: Technology, Discovery, and Translation. Journal of Clinical Oncology, 2012, 30, 647-660.	1.6	173
123	Therapyâ€related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. Cancer, 2012, 118, 3962-3967.	4.1	47
124	Influence of FLT3â€internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediateâ€risk karyotype acute myeloid leukemia. Cancer, 2012, 118, 6110-6117.	4.1	36
125	The use of FTA cards for preserving unfixed cytological material for highâ€ŧhroughput molecular analysis. Cancer Cytopathology, 2012, 120, 206-214.	2.4	36
126	Phase II study of PX-866 in recurrent glioblastoma Journal of Clinical Oncology, 2012, 30, 2051-2051.	1.6	0

#	Article	IF	CITATIONS
127	A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis. Blood, 2012, 120, 1586-1586.	1.4	0
128	BCR/ABL Transcript At 3 Months Predicts Long-Term Outcomes Following Second Generation Tyrosine Kinase Inhibitor Therapy in the Patients with CML in Chronic Phase Who Failed Imatinib Blood, 2012, 120, 2777-2777.	1.4	1
129	A gene signature in histologically normal surgical margins is predictive of oral carcinoma recurrence. BMC Cancer, 2011, 11, 437.	2.6	117
130	mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnology, 2011, 11, 46.	3.3	234
131	The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head & Neck Oncology, 2011, 3, 11.	2.3	75
132	Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. Leukemia Research, 2011, 35, 492-498.	0.8	18
133	Correlation among nuclear localization of NuMA-RARα, deregulation of gene expression and leukemic phenotype of hCG-NuMA-RARα transgenic mice. Leukemia Research, 2011, 35, 670-676.	0.8	3
134	Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. Journal of Clinical Oncology, 2011, 29, 3278-3285.	1.6	321
135	Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. Blood, 2011, 118, 606-606.	1.4	3
136	A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemotherapy and Pharmacology, 2010, 65, 353-361.	2.3	172
137	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer, 2010, 116, 5599-5607.	4.1	143
138	Targeted use of fluorescence in situ hybridization (FISH) in cytospin preparations. Cancer Cytopathology, 2010, 118, 250-258.	2.4	49
139	Detection of <i>EGFR</i> and <i>KRAS</i> mutations in fineâ€needle aspirates stored on Whatman FTA cards. Cancer Cytopathology, 2010, 118, 450-456.	2.4	46
140	Comprehensive evaluation of timeâ€toâ€response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: Which parameter at which timeâ€point does matter?. American Journal of Hematology, 2010, 85, 856-862.	4.1	10
141	Optimization and analysis of a quantitative real-time PCR-based technique to determine microRNA expression in formalin-fixed paraffin-embedded samples. BMC Biotechnology, 2010, 10, 47.	3.3	39
142	Low prevalence of Human Papillomavirus in oral cavity carcinomas. Head & Neck Oncology, 2010, 2, 6.	2.3	75
143	SATB2 augments ΔNp63α in head and neck squamous cell carcinoma. EMBO Reports, 2010, 11, 777-783.	4.5	50
144	KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies. Current Oncology, 2010, 17, 31-40.	2.2	54

9

#	Article	IF	CITATIONS
145	Cytoplasmic Expression of Nucleophosmin Accurately Predicts Mutation in the Nucleophosmin Gene in Patients With Acute Myeloid Leukemia and Normal Karyotype. American Journal of Clinical Pathology, 2010, 133, 34-40.	0.7	34
146	The <i>IFNG</i> (IFN-γ) Genotype Predicts Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5339-5350.	7.0	29
147	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood, 2010, 116, e111-e117.	1.4	141
148	Programmed cell death 4 loss increases tumor cell invasion and is regulated by miR-21 in oral squamous cell carcinoma. Molecular Cancer, 2010, 9, 238.	19.2	121
149	A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leukemia and Lymphoma, 2010, 51, 252-260.	1.3	85
150	A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial. Blood, 2010, 116, LBA-6-LBA-6.	1.4	22
151	Identification ofÂgenomic predictors ofÂnon-melanoma skin cancer inÂsolid organ transplant recipients. European Journal of Dermatology, 2009, 19, 278-280.	0.6	4
152	Applications of Microarray Technology to Acute Myelogenous Leukemia. Cancer Informatics, 2009, 7, CIN.S1015.	1.9	11
153	Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Human Molecular Genetics, 2009, 18, 4818-4829.	2.9	223
154	Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia. Clinical Cancer Research, 2009, 15, 4750-4758.	7.0	170
155	Postal survey of physicians and laboratories: Practices and perceptions of molecular oncology testing. BMC Health Services Research, 2009, 9, 131.	2.2	30
156	Treatment of adults with BCRâ€ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. British Journal of Haematology, 2009, 146, 76-85.	2.5	137
157	Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia. Journal of Molecular Diagnostics, 2009, 11, 4-11.	2.8	72
158	microRNA evaluation of unknown primary lesions in the head and neck. Molecular Cancer, 2009, 8, 127.	19.2	59
159	Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica, 2009, 94, 135-139.	3.5	137
160	IFN-γ (interferon-gamma) Genotype Predict Cytogenetic and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukemia Blood, 2009, 114, 2178-2178.	1.4	0
161	Comprehensive Evaluation of Time-to-Response Parameter as a Predictor of Long-Term Outcomes Following Imatinib Therapy in Chronic Phase Chronic Myeloid Leukemia Blood, 2009, 114, 1110-1110.	1.4	8
162	Low-Level FLT3-ITD Mutations Do Not Predict for Higher Relapse Rate in AML with Standard Risk Karyotpye Blood, 2009, 114, 1591-1591.	1.4	0

#	Article	IF	CITATIONS
163	Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Cancer, 2008, 112, 1513-1521.	4.1	22
164	No significance of derivative chromosome 9 deletion on the clearance kinetics of <i>BCR</i> / <i>ABL</i> fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Cancer, 2008, 113, 772-781.	4.1	29
165	Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. Cancer, 2008, 113, 3169-3180.	4.1	105
166	Lung transplantation complicated by graftâ€versusâ€host disease and confounded by incidental transfusionâ€associated macrochimerism. Transfusion, 2008, 48, 2190-2196.	1.6	12
167	Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2008, 26, 4268-4275.	1.6	674
168	A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies. Clinical Cancer Research, 2008, 14, 8295-8301.	7.0	183
169	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood, 2008, 112, 3330-3338.	1.4	350
170	Natural Killer (NK) or NK/T Cell Lineage Large Granular Lymphocytosis Associated with Dasatinib Therapy for Philadelphia Chromosome Positive Leukemia Blood, 2008, 112, 933-933.	1.4	2
171	Assessment of Microrna Expression in Mantle Cell Lymphoma Using High Throughput Techniques. Blood, 2008, 112, 2824-2824.	1.4	0
172	Clinical Relevance of Vascular Endothelial Growth Factor (VEGFA) and VEGF Receptor (VEGFR2) Gene Single Nucleotide Polymorphism on the Treatment Outcomes Following Imatinib Mesylate Therapy Blood, 2008, 112, 1110-1110.	1.4	1
173	Deregulation of Transcription Factors GATA-1, GATA-2 and C/EBPa in Acute Promyelocytic Leukemia Blood, 2008, 112, 2241-2241.	1.4	1
174	Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. Journal of Clinical Oncology, 2007, 25, 2184-2190.	1.6	92
175	Acute promyelocytic leukemia in patients aged 70 years and over—A single center experience of unselected patients. Leukemia and Lymphoma, 2007, 48, 1654-1658.	1.3	18
176	Vanishing Endometrial Carcinoma. International Journal of Gynecological Pathology, 2007, 26, 271-277.	1.4	10
177	Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5) Tj ETQq1 1 0.	784314 rg 1.3	gBT_{3}Overlock
178	Inter-Laboratory Comparison of Chronic Myeloid Leukemia Minimal Residual Disease Monitoring. Journal of Molecular Diagnostics, 2007, 9, 421-430.	2.8	54
179	Absence of FTL3 mutations in patients withJAK2V617F mutation negative essential thrombocythemia. American Journal of Hematology, 2007, 82, 293-294.	4.1	3
180	Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stemcell transplantation. American Journal of Hematology, 2007, 82, 758-760.	4.1	4

#	Article	IF	CITATIONS
181	Presence of t(1;14)(p13;p11.2) in Philadelphia chromosome–negative cells in a patient with chronic myeloid leukemia. Cancer Genetics and Cytogenetics, 2007, 173, 83-84.	1.0	1
182	Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006, 108, 28-37.	1.4	1,117
183	Young Patients With Oral Squamous Cell Carcinoma. JAMA Otolaryngology, 2006, 132, 958.	1.2	35
184	Lymphatic Vessel Density, Nodal Metastases, and Prognosis in Patients With Head and Neck Cancer. JAMA Otolaryngology, 2005, 131, 1065.	1.2	59
185	Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse model. Laboratory Investigation, 2005, 85, 947-961.	3.7	10
186	A novel method of measuring gas phase nitric oxide concentration in cell cultures. Acta Oto-Laryngologica, 2005, 125, 1086-1090.	0.9	0
187	T-Cell Large Granular Lymphocytic Leukemia of Donor Origin Occurring After Allogeneic Bone Marrow Transplantation for B-Cell Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2005, 123, 196-199.	0.7	31
188	Molecular Genetic Analysis of Oligodendroglial Tumors. Journal of Neuropathology and Experimental Neurology, 2005, 64, 10-14.	1.7	49
189	Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome. New England Journal of Medicine, 2005, 353, 133-144.	27.0	1,787
190	Nonmyeloablative Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients 60 Years or Older. Biology of Blood and Marrow Transplantation, 2005, 11, 764-772.	2.0	67
191	A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. European Journal of Cancer, 2005, 41, 523-530.	2.8	86
192	T-cell large granular lymphocytic leukemia of donor origin occurring after allogeneic bone marrow transplantation for B-cell lymphoproliferative disorders. American Journal of Clinical Pathology, 2005, 123, 196-9.	0.7	9
193	Clinico-Biological Features and Prognostic Significance of PML/RARα Isoforms in Adult Patients with Acute Promyelocytic Leukemia Treated with All Trans Retinoic Acid (ATRA) and Chemotherapy. Leukemia and Lymphoma, 2004, 45, 469-480.	1.3	13
194	Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARα. Oncogene, 2004, 23, 665-678.	5.9	38
195	Current Applications of Microarrays in Head and Neck Cancer Research. Laryngoscope, 2004, 114, 241-248.	2.0	19
196	Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: A pilot study. Head and Neck, 2004, 26, 815-822.	2.0	25
197	Cryptic insertion ofMLL gene into 9p22 leads toMLL-MLLT3 (AF9) fusion in a case of acute myelogenous leukemia. Genes Chromosomes and Cancer, 2004, 40, 349-354.	2.8	10
198	Molecular classification of oral cancer by cDNA microarrays identifies overexpressed genes correlated with nodal metastasis. International Journal of Cancer, 2004, 110, 857-868.	5.1	57

#	Article	IF	CITATIONS
199	Acute leukemia of donor origin arising after stem cell transplantation for acute promyelocytic leukemia. Leukemia Research, 2004, 28, 1107-1111.	0.8	16
200	EAR-2: Identification of a Gene Involved in Maintenance of Clonogenicity in Haematopoiesis Blood, 2004, 104, 3226-3226.	1.4	0
201	Disordered Expression of HIPK Family Members in MDS and AML Blood, 2004, 104, 4311-4311.	1.4	2
202	Expression of NPM-RARα fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis. Oncogene, 2003, 22, 6424-6435.	5.9	14
203	Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. Blood, 2002, 99, 2387-2396.	1.4	48
204	Molecular Analysis of a New Variant of the CBFÎ ² - MYH11 Gene Fusion. Leukemia and Lymphoma, 2002, 43, 2021-2026.	1.3	6
205	Microarray and Biochemical Analysis of Lovastatin-induced Apoptosis of Squamous Cell Carcinomas. Neoplasia, 2002, 4, 337-346.	5.3	82
206	Molecular cytogenetic analysis of head and neck squamous cell carcinoma: By comparative genomic hybridization, spectral karyotyping, and expression array analysis. Head and Neck, 2002, 24, 874-887.	2.0	81
207	Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. Oncogene, 2002, 21, 6480-6487.	5.9	44
208	High frequency of microsatellite instability in young patients with head-and-neck squamous-cell carcinoma: Lack of involvement of the mismatch repair geneshMLH1 ANDhMSH2. International Journal of Cancer, 2001, 93, 353-360.	5.1	67
209	Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma. Oncogene, 2001, 20, 654-658.	5.9	39
210	Primary Low-Grade B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue Type Arising in the Urinary Bladder. Archives of Pathology and Laboratory Medicine, 2001, 125, 332-336.	2.5	54
211	Exon-skipping in BCR/ABL is induced by ABL exon 2. Biochemical Journal, 2000, 348, 63.	3.7	3
212	Exon-skipping in BCR/ABL is induced by ABL exon 2. Biochemical Journal, 2000, 348, 63-69.	3.7	7
213	Co-localization of Patched and activated Sonic hedgehog to lysosomes in neurons. NeuroReport, 2000, 11, 581-585.	1.2	27
214	Telomerase Activity Is Upregulated in Laryngeal Squamous Cell Carcinoma. Laryngoscope, 2000, 110, 391-396.	2.0	22
215	Deregulation of NPM and PLZF in a variant t(5;17) case of acute promyelocytic leukemia. Oncogene, 1999, 18, 633-641.	5.9	59
216	Detection of occult low-grade B-cell non-hodgkin's lymphoma in patients with chronic hepatitis C infection and mixed cryoglobulinemia. Hepatology, 1999, 29, 543-547.	7.3	99

#	ARTICLE	IF	CITATIONS
217	Skeletal dysplasias with gracile bones: Three new cases, including two offspring of a mother with a dwarfing condition. , 1998, 76, 125-132.		17
218	Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. British Journal of Haematology, 1998, 103, 711-715.	2.5	53
219	Telomerase Activity in Oral Squamous Cell Carcinoma. JAMA Otolaryngology, 1998, 124, 784.	1.2	21
220	Fusion of retinoic acid receptor $\hat{l}\pm$ to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia. Nature Genetics, 1997, 17, 109-113.	21.4	276
221	Preclinical Assessment of Human Hematopoietic Progenitor Cell Transduction in Long-Term Marrow Cultures. Human Gene Therapy, 1996, 7, 2089-2100.	2.7	12
222	Endogenous Murine Leukemia Virus DNA Sequences in Murine Cell Lines: Implications for Gene Therapy Safety Testing by PCR. Leukemia and Lymphoma, 1996, 23, 375-381.	1.3	7
223	Dysregulation of HOX11 by Chromosome Translocations in T-cell Acute Lymphoblastic Leukemia: A Paradigm for Homeobox Gene Involvement in Human Cancer. Leukemia and Lymphoma, 1995, 16, 209-215.	1.3	26